Viking Therapeutics Stock Performance
| VKTX Stock | USD 51.63 0.10 0.19% |
The entity has a beta of -0.63, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Viking Therapeutics are expected to decrease at a much lower rate. During the bear market, Viking Therapeutics is likely to outperform the market. At this point, Viking Therapeutics has a negative expected return of -0.24%. Please make sure to validate Viking Therapeutics' value at risk, rate of daily change, relative strength index, as well as the relationship between the kurtosis and market facilitation index , to decide if Viking Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Viking Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 36.6 M |
Viking |
Viking Therapeutics Relative Risk vs. Return Landscape
If you would invest 6,552 in Viking Therapeutics on August 24, 2024 and sell it today you would lose (1,389) from holding Viking Therapeutics or give up 21.2% of portfolio value over 90 days. Viking Therapeutics is currently does not generate positive expected returns and assumes 5.1462% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Viking, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Viking Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viking Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Viking Therapeutics, and traders can use it to determine the average amount a Viking Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0474
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VKTX |
Estimated Market Risk
| 5.15 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Viking Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Viking Therapeutics by adding Viking Therapeutics to a well-diversified portfolio.
Viking Therapeutics Fundamentals Growth
Viking Stock prices reflect investors' perceptions of the future prospects and financial health of Viking Therapeutics, and Viking Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Viking Stock performance.
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.13 | ||||
| Current Valuation | 4.81 B | ||||
| Shares Outstanding | 111.44 M | ||||
| Price To Earning | (3.17) X | ||||
| Price To Book | 6.30 X | ||||
| EBITDA | (100.83 M) | ||||
| Cash And Equivalents | 155.02 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 1.26 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 8.18 X | ||||
| Cash Flow From Operations | (73.38 M) | ||||
| Earnings Per Share | (0.94) X | ||||
| Total Asset | 368.49 M | ||||
| Retained Earnings | (377.94 M) | ||||
| Current Asset | 15.2 M | ||||
| Current Liabilities | 1.98 M | ||||
About Viking Therapeutics Performance
Evaluating Viking Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Viking Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Viking Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company was incorporated in 2012 and is headquartered in San Diego, California. Viking Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.Things to note about Viking Therapeutics performance evaluation
Checking the ongoing alerts about Viking Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Viking Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Viking Therapeutics generated a negative expected return over the last 90 days | |
| Viking Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (85.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Viking Therapeutics currently holds about 155.02 M in cash with (73.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.02. | |
| Over 75.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Viking Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Viking Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Viking Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Viking Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Viking Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Viking Therapeutics' stock. These opinions can provide insight into Viking Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Viking Stock Analysis
When running Viking Therapeutics' price analysis, check to measure Viking Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viking Therapeutics is operating at the current time. Most of Viking Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viking Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viking Therapeutics' price. Additionally, you may evaluate how the addition of Viking Therapeutics to your portfolios can decrease your overall portfolio volatility.